A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients

• Published in: Journal of neuroimmunology Vol. 292; pp. 34 - 39
• Main Authors: Martire, Serena, Navone, Nicole D, Montarolo, Francesca, Perga, Simona, Bertolotto, Antonio
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15-03-2016
• Subjects: Adolescent; Adult; Allergy and Immunology; Biomarkers; Biomarkers - blood; Cytokines - genetics; Cytokines - metabolism; Female; Gene expression; Gene Expression - drug effects; Humans; Interferon-beta; Interferon-beta - therapeutic use; Male; Middle Aged; Multiple sclerosis; Multiple Sclerosis - diagnosis; Multiple Sclerosis - drug therapy; Neurology; Retrospective Studies; RNA, Messenger - metabolism; Statistics, Nonparametric; Treatment response; Young Adult; Biomarkers; Multiple sclerosis; Treatment response; Interferon-beta; Gene expression
• ISSN: 0165-5728; 1872-8421
• DOI: 10.1016/j.jneuroim.2016.01.010

Abstract We studied the baseline expression level of 25 interferon-regulated genes (MxA, GPR3, IL17RC, ISG15, TRAIL, OASL, IFIT1, IFIT2, RSAD2, OAS3, IFI44L, TRIM22, IL10, CXCL10, STAT1, OAS1, OAS2, IFNAR1, IFNAR2, IFNβ, ISG20, IFI6, PKR, IRF7, USP18), recurrently proposed in the literature as predictive biomarkers of interferon-beta treatment response, in whole blood of 10 “responders” and 10 “non-responders” multiple sclerosis relapsing–remitting patients, retrospectively selected on the basis of stringent clinical criteria after a five years follow-up. However, we cannot confirm the predictive value of these candidate biomarkers.